Literature DB >> 15466246

A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.

Hidemitsu Nakajima1, Nobukazu Kakui, Kunihiro Ohkuma, Midori Ishikawa, Toshifumi Hasegawa.   

Abstract

We investigated the pharmacological profiles of DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one], a newly synthesized poly(ADP-ribose) polymerase (PARP) inhibitor, and its neuroprotective effects on ischemic injuries in vitro and in vivo. DR2313 competitively inhibited poly(ADP-ribosyl)ation in nuclear extracts of rat brain in vitro (K(i) = 0.23 microM). Among several NAD(+)-utilizing enzymes, DR2313 was specific for PARP but not selective between PARP-1 and PARP-2. DR2313 also showed excellent profiles in water solubility and rat brain penetrability. In in vitro models of cerebral ischemia, exposure to hydrogen peroxide or glutamate induced cell death with overactivation of PARP, and treatment with DR2313 reduced excessive formation of poly(ADP-ribose) and cell death. In both permanent and transient focal ischemia models in rats, pretreatment with DR2313 (10 mg/kg i.v. bolus and 10 mg/kg/h i.v. infusion for 6 h) significantly reduced the cortical infarct volume. To determine the therapeutic time window of neuroprotection by DR2313, the effect of post-treatment was examined in transient focal ischemia model and compared with that of a free radical scavenger, MCI-186 (3-methyl-1-phenyl-2-pyrazolone-5-one). Pretreatment with MCI-186 (3 mg/kg i.v. bolus and 3 mg/kg/h i.v. infusion for 6 h) significantly reduced the infarct volume, whereas the post-treatment failed to show any effects. In contrast, post-treatment with DR2313 (same regimen) delaying for 2 h after ischemia still prevented the progression of infarction. These results indicate that DR2313 exerts neuroprotective effects via its potent PARP inhibition, even when the treatment is initiated after ischemia. Thus, a PARP inhibitor like DR2313 may be more useful in treating acute stroke than a free radical scavenger.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466246     DOI: 10.1124/jpet.104.075465

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold.

Authors:  Junya Kawai; Masahiro Ota; Hitoshi Ohki; Tadashi Toki; Makoto Suzuki; Takashi Shimada; Satoshi Matsui; Hidekazu Inoue; Chika Sugihara; Norikazu Matsuhashi; Yumi Matsui; Sachiko Takaishi; Kiyoshi Nakayama
Journal:  ACS Med Chem Lett       Date:  2019-05-24       Impact factor: 4.345

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

3.  Nicotinamide prevents the effect of perinatal asphyxia on dopamine release evaluated with in vivo microdialysis 3 months after birth.

Authors:  Diego Bustamante; Paola Morales; Jorge Torres Pereyra; Michel Goiny; Mario Herrera-Marschitz
Journal:  Exp Brain Res       Date:  2007-03       Impact factor: 1.972

4.  Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia.

Authors:  Zhenfeng Xu; Jian Zhang; Karen K David; Zeng-Jin Yang; Xiaoling Li; Ted M Dawson; Valina L Dawson; Raymond C Koehler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

5.  Nuclear-translocated Glyceraldehyde-3-phosphate Dehydrogenase Promotes Poly(ADP-ribose) Polymerase-1 Activation during Oxidative/Nitrosative Stress in Stroke.

Authors:  Hidemitsu Nakajima; Takeya Kubo; Hideshi Ihara; Takatoshi Hikida; Teruko Danjo; Masatoshi Nakatsuji; Neelam Shahani; Masanori Itakura; Yoko Ono; Yasu-Taka Azuma; Takashi Inui; Atsushi Kamiya; Akira Sawa; Tadayoshi Takeuchi
Journal:  J Biol Chem       Date:  2015-04-16       Impact factor: 5.157

6.  Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats.

Authors:  Paola Morales; Nicola Simola; Diego Bustamante; Francisco Lisboa; Jenny Fiedler; Peter J Gebicke-Haerter; Micaela Morelli; R Andrew Tasker; Mario Herrera-Marschitz
Journal:  Exp Brain Res       Date:  2009-12-11       Impact factor: 1.972

7.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

9.  Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.

Authors:  Jian Zhang; Xiaoling Li; Herman Kwansa; Yun Tai Kim; Liye Yi; Gina Hong; Shaida A Andrabi; Valina L Dawson; Ted M Dawson; Raymond C Koehler; Zeng-Jin Yang
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

10.  Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.

Authors:  Salomé C Vilchez Larrea; Teemu Haikarainen; Mohit Narwal; Mariana Schlesinger; Harikanth Venkannagari; Mirtha M Flawiá; Silvia H Fernández Villamil; Lari Lehtiö
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.